… Platinum-based chemotherapy plus cetuximab in head and neck cancer. … versus cetuximab
with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck …

… Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (… have been tested in HNSCC, cetuximab, an IgG1 subclass …

… Head and neck squamous cell carcinoma (HNSCC) includes cancers of the oral cavity,
oropharynx, hypopharynx, and larynx. Locoregional HNSCC is treated with curative intent, …

… Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with
recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who …

… new cases of head and neck cancers worldwide, with … percent of head and neck cancers are
squamous cell carcinoma (… {5-FU}] plus cetuximab followed by cetuximab maintenance until …

… Currently, cetuximab associated with radiotherapy is limited to the … cetuximab efficacy in
this cancer setting are still lacking. This review focuses on the mechanisms of action of cetuximab…

… Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR … or metastatic head and neck squamous
cell carcinoma (HNSCC). … or metastatic squamous cell carcinoma of the head and neck …

… Cancer of the head and neck accounts for >550,000 new cases annually worldwide (1, 2).
About 90% of all head and neck cancers are squamous cell carcinomas … of the head and neck (…

… -L1) monotherapy for squamous cell carcinoma of the head and neck—the CheckMate 141
study of nivolumab versus investigator's choice of docetaxel, methotrexate, or cetuximab for …

… Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab
[a … While biomarkers of resistance to cetuximab have been identified in metastatic colorectal …